Oncotelic Completes Phase 2 of AI Manufacturing Platform with TechForce Robotics

Oncotelic Therapeutics (OTCQB: OTLC) has announced the successful completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, marking a significant step toward commercializing an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic’s proprietary PDAOAI(TM) platform across critical areas including sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring, and autonomous materials movement. This integration combines PDAOAI(TM) with TechForce’s autonomous robotic systems to support intelligent pharmaceutical manufacturing, creating potential revenue opportunities in software licensing, automation deployment, manufacturing partnerships, and technology-enabled contract development and manufacturing services (CDMO). Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization within the pharmaceutical manufacturing sector.

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company’s pipeline is complemented by a robust portfolio of inventions from its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Beyond direct drug development, Oncotelic leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. The company also licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including its 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates. The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC.

This development underscores Oncotelic’s commitment to integrating cutting-edge AI and robotics into pharmaceutical manufacturing, positioning the company to offer advanced solutions that could improve efficiency, compliance, and scalability in sterile drug production. The collaboration with TechForce Robotics and the focus on the PDAOAI(TM) platform highlight a strategic shift toward becoming a technology-enabled CDMO, potentially opening new revenue streams beyond traditional drug development. For investors, the successful Phase 2 deployment signals progress in the company’s business model evolution, while for the pharmaceutical industry, it represents a tangible example of how AI and automation can transform manufacturing processes to meet stringent GMP standards.